Sarah Boyce
CIK 1629383 · President and CEO · last filed 2026-06-26
Sarah Boyce is a President and CEO who has filed 67 SEC Form 4 insider transactions across 9 companies since 2015. The most recent filing, for CTNM, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$33.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.66M
9
67
-$33.85M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTNM | Director | — | $14.16 | — | $0 | 3 | 2026-06-26 |
| Avidity Biosciences, Inc. (RNAM) Delisted | President and CEO | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | President and CEO | 277,000 | $11.49 | $3.18M | -$33.09M | 27 | 2026-01-23 |
| OABIW | Director | 104,381 | $0.08 | $8.7K | $101.4K | 5 | 2024-06-21 |
| LGND | Director | 2,892 | $296.28 | $856.8K | $0 | 5 | 2022-11-03 |
| Bruker Cellular Analysis, Inc. (BLI) Delisted | Director | 1,400 | $1.20 | $1.7K | -$611.3K | 2 | 2021-05-18 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | President | 19,888 | — | — | -$42.8K | 4 | 2019-07-17 |
| IONS | Chief Business Officer | 11,127 | $55.30 | $615.3K | -$212.8K | 8 | 2018-01-17 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Chief Business Officer | — | — | — | $0 | 2 | 2015-01-20 |
Recent Filings
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | CTNM | Grant (A) | — | $0 | EDGAR |
| 2026-03-02 | — | Grant (A) | — | $0 | |
| 2026-02-27 | Avidity Biosciences, Inc. (RNAM) Delisted | Disp (D) | −474,861 | $0 | EDGAR |
| 2026-01-23 | RNA | Sell (S) | −14,387 | -$1.04M | EDGAR |
| 2026-01-09 | RNA | Sell (S) | −8,576 | -$619.4K | EDGAR |
| 2025-12-19 | RNA | Mixed | −13,901 | -$1.13M | EDGAR |
| 2025-09-05 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −50,000 | -$2.42M | EDGAR |
| 2025-09-05 | RNA | Mixed | — | -$2.44M | EDGAR |
| 2025-08-29 | RNA | Mixed | — | -$1.20M | EDGAR |
| 2025-08-28 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −25,000 | -$1.20M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.